Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24313774 | 0.89 | TRIM24 (0.41) | MCHR1KCNH2L3MBTL1TRIM24BRPF1 | |
| SCHEMBL24314184 | 0.86 | ALDH1A1 (0.43) | MCHR1KCNH2L3MBTL1TRIM24BRPF1 | |
| SCHEMBL29587808 | 0.86 | ALDH1A1 (0.43) | MCHR1KCNH2L3MBTL1TRIM24BRPF1 | |
| SCHEMBL24333754 | 0.83 | L3MBTL1 (0.38) | MCHR1KCNH2L3MBTL1THRBTSHR | |
| SCHEMBL24314247 | 0.82 | MEN1 (0.36) | L3MBTL1TSHRTRIM24MEN1ALDH1A1 | |
| SCHEMBL24314237 | 0.81 | MRGPRX1 (0.38) | MCHR1KCNH2L3MBTL1TSHRMEN1 | |
| SCHEMBL24313811 | 0.81 | MCHR1 (0.38) | MCHR1KCNH2L3MBTL1POLBALDH1A1 | |
| SCHEMBL24313760 | 0.80 | SCN9A (0.35) | L3MBTL1TSHRMEN1ALDH1A1KMT2A | |
| SCHEMBL24333741 | 0.78 | TRIM24 (0.41) | MCHR1KCNH2L3MBTL1TRIM24BRPF1 | |
| SCHEMBL24313979 | 0.78 | CYP1A2 (0.37) | MCHR1KCNH2L3MBTL1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229045-B1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BROAD INST INC (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4229045-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute Inc. (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-29 | — | — | US | disclosed |
| EP-4229045-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | MCHR1 4391/4885KCNH2 1005/4885L3MBTL1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.